Editor’s Choice

Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects

Obesity is an increasing problem worldwide.  This has resulted in confusion on the dosing of drugs in this population.  This month’s Editor’s Choice article examines the dosing of tedizolid in obese and non-obese individuals. The authors showed minor differences between the 2 groups of subjects in terms of the pharmacokinetics of the drug. This translates into no difference in attaining the target pharmacodynamic parameter needed to eradicate bacteria.  Dosing of tedizolid does not need to be adjusted in obese vs. non-obese individuals.

Download the JCP App

iOS App for iPad or iPhone

Download The Journal of Clinical Pharmacology App from the Apple Store